Merkel cell carcinoma: More deaths but still no pathway to blame

Journal of Investigative Dermatology

Volumn 127, Issue 9, 2007, Pages 2100-2103

  Lemos, Bianca ^a   Nghiem, Paul ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 20; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

AGING; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; INCIDENCE; MELANOMA; MERKEL CELL TUMOR; MOLECULAR BIOLOGY; MORTALITY; NEUROENDOCRINE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION CARCINOGENESIS; REVIEW; RISK FACTOR; SKIN CARCINOGENESIS; SUN EXPOSURE; ULTRAVIOLET RADIATION;

EID: 34547899952     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700925     Document Type: Note

References (16)

1. Agelli M, Clegg LX (2003) Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 49:832-41
2. American Cancer Society (2006) Cancer Facts and Figures 2006. 〈http://www.cancer.org/docroot/STT/content/ STT_1x_Cancer_Facts__Figures_2006.asP〉
3. Hodgson NC (2005) Merkel cell carcinoma: changing incidence trends. J Surg Oncol 89:1-4
4. Houben R, Michel B, Vetter-Kauczok CS, Pfohler C, Laetsch B, Wolter MD et al. (2006) Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol 126:1135-42
5. Houben R, Ortmann, S, Schrama D, Herold MJ, Berberich I, Reichardt HM et al. (2007) Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol 127:2116-22
6. Kennedy MM, Blessing K, King G, Kerr KM (1996) Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol 18:273-7
7. Liu S, Daa T, Kashima K, Kondoh Y, Yokoyama S (2007) The Wnt-signaling pathway is not implicated in tumorigenesis of Merkel cell carcinoma. J Cutan Pathol 34:22-6
8. Plettenberg A, Pammer J, Tschachler E (1996) Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene. Exp Dermatol 5:183-8
9. Popp S, Waltering S, Herbst C, Moll I, Boukamp P (2002) UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 99:352-60
10. Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, et al. (2000) Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 114:725-30
11. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308
12. Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA (2007) Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate. J Cutan Pathol 34:324-9
13. Van Gele M, Kaghad M, Leonard JH, Van Roy N, Naeyaert JM, Geerts ML et al. (2000) Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer 82:823-6
14. Van Gele M, Leonard JH, Van Roy N, Cook AL, De Paepe A, Speleman F (2001) Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma. Int J Cancer 92:409-13
15. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H (2005) ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 4:910-7
16. Weinstock MA, Gardstein B (1999) Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 89:1240-4